Publication:
One-year post-vaccination longitudinal follow-up of quantitative sars-cov-2 anti-spike total antibodies in health care professionals and evaluation of correlation with surrogate neutralization test

Simple item page
dc.contributor.authorHASDEMİR GÖKBOĞA, MÜNEVVER UFUK
dc.contributor.authorsTuyji Tok Y., Can Sarinoglu R., Ordekci S., Yilmaz S., Ozcolpan G., Bayram A., NOHUT O. K., Kocer I., HASDEMİR GÖKBOĞA M. U., Kuskucu M. A., et al.
dc.date.accessioned2023-03-21T07:20:15Z
dc.date.available2023-03-21T07:20:15Z
dc.date.issued2023-02-01
dc.description.abstractNumerous vaccines have been generated to decrease the morbidity and mortality of COVID-19. This study aims to evaluate the immunogenicity of the heterologous boosts by BioNTech against homologous boosts by CoronaVac at three-month intervals in two health care worker (HCW) cohorts, with or without prior COVID-19, for one year post-vaccination. This is a prospective cohort study in which the humoral responses of 386 HCWs were followed-up longitudinally in six main groups according to their previous COVID-19 exposure and vaccination status. Anti-SARS-CoV-2 spike-RBD total antibody levels were measured and SARS-CoV-2 neutralization antibody (NAbs) responses against the ancestral Wuhan and the Omicron variant were evaluated comparatively using international standard serum for Wuhan and Omicron, as well as with the aid of a conversion tool. The anti-SARS-CoV-2 spike-RBD total Ab and Nab difference between with and without prior COVID-19, three months after two-dose primary vaccination with CoronaVac, was statistically significant (p = 0.001). In the subsequent follow-ups, this difference was not observed between the groups. Those previously infected (PI) and non-previously infected (NPI) groups receiving BioNTech as the third dose had higher anti-SARS-CoV-2 spike total Ab levels (14.2-fold and 17.4-fold, respectively, p = 0.001) and Nab responses (against Wuhan and Omicron) than those receiving CoronaVac. Ab responses after booster vaccination decreased significantly in all groups at the ninth-month follow-up (p < 0.05); however, Abs were still higher in all booster received groups than that in the primary vaccination. Abs were above the protective level at the twelfth-month measurement in the entire of the second BioNTech received group as the fourth dose of vaccination. In the one-year follow-up period, the increased incidence of COVID-19 in the groups vaccinated with two or three doses of CoronaVac compared with the groups vaccinated with BioNTech as a booster suggested that continuing the heterologous CoronaVac/BioNTech vaccination, revised according to current SARS-CoV-2 variants and with at least a six-month interval booster would be an effective and safe strategy for protection against COVID-19, particularly in health care workers.
dc.identifier.citationTuyji Tok Y., Can Sarinoglu R., Ordekci S., Yilmaz S., Ozcolpan G., Bayram A., NOHUT O. K., Kocer I., HASDEMİR GÖKBOĞA M. U., Kuskucu M. A., et al., "One-Year Post-Vaccination Longitudinal Follow-Up of Quantitative SARS-CoV-2 Anti-Spike Total Antibodies in Health Care Professionals and Evaluation of Correlation with Surrogate Neutralization Test", Vaccines, cilt.11, sa.2, 2023
dc.identifier.doi10.3390/vaccines11020355
dc.identifier.issn2076-393X
dc.identifier.issue2
dc.identifier.urihttps://avesis.marmara.edu.tr/api/publication/6561655f-290c-43a5-b0a2-00ab4c0df0da/file
dc.identifier.urihttps://hdl.handle.net/11424/287681
dc.identifier.volume11
dc.language.isoeng
dc.relation.ispartofVaccines
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTemel Eczacılık Bilimleri
dc.subjectEczacılık
dc.subjectYaşam Bilimleri
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectSitogenetik
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectBasic Pharmaceutics Sciences
dc.subjectPharmacology and Therapeutics
dc.subjectLife Sciences
dc.subjectMolecular Biology and Genetics
dc.subjectCytogenetic
dc.subjectHealth Sciences
dc.subjectNatural Sciences
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectİmmünoloji
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectBULAŞICI HASTALIKLAR
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectBİYOKİMYA VE MOLEKÜLER BİYOLOJİ
dc.subjectLife Sciences (LIFE)
dc.subjectIMMUNOLOGY
dc.subjectPHARMACOLOGY & TOXICOLOGY
dc.subjectMOLECULAR BIOLOGY & GENETICS
dc.subjectINFECTIOUS DISEASES
dc.subjectPHARMACOLOGY & PHARMACY
dc.subjectBIOCHEMISTRY & MOLECULAR BIOLOGY
dc.subjectFarmakoloji
dc.subjectİlaç Keşfi
dc.subjectBulaşıcı hastalıklar
dc.subjectFarmakoloji (tıbbi)
dc.subjectImmunology
dc.subjectPharmacology
dc.subjectDrug Discovery
dc.subjectInfectious Diseases
dc.subjectPharmacology (medical)
dc.subjectCOVID-19
dc.subjectheterologous
dc.subjectinactivated
dc.subjectmRNA
dc.subjectvaccine
dc.titleOne-year post-vaccination longitudinal follow-up of quantitative sars-cov-2 anti-spike total antibodies in health care professionals and evaluation of correlation with surrogate neutralization test
dc.typearticle
dspace.entity.typePublication
local.avesis.id6561655f-290c-43a5-b0a2-00ab4c0df0da
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublicationc6059919-1fb4-499b-84ad-9afa4bb224d8
relation.isAuthorOfPublication.latestForDiscoveryc6059919-1fb4-499b-84ad-9afa4bb224d8

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
4.pdf
Size:
10.03 MB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs